Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing, Innovation & Presidential Politics: Today’s Shocking News

This article was originally published in RPM Report

Executive Summary

Over the last six months, drug pricing has been a headline issue in no small part thanks to the dynamics of Presidential politics. But latest news about former President Jimmy Carter is a reminder that there is another side of the issue.

You may also be interested in...



A New Idea To Solve The Turing Problem – If Anyone Notices

The Fair Pricing Coalition previewed its upcoming ‘first hundred days’ proposal for drug pricing reforms – one of many Washington policy documents that was prepared with a very different election result in mind. But one new idea in the report deserves serious attention because it would actually directly address the ‘repricing’ strategy that drove the headlines over the past year.

A New Idea To Solve The Turing Problem – If Anyone Notices

The Fair Pricing Coalition previewed its upcoming ‘first hundred days’ proposal for drug pricing reforms – one of many Washington policy documents that was prepared with a very different election result in mind. But one new idea in the report deserves serious attention because it would actually directly address the ‘repricing’ strategy that drove the headlines over the past year.

Clinton Vs. Trump: Three Scenarios For Biopharma

The presidential campaign is about to begin in earnest, and for biopharma companies, the biggest question is what the outcome will mean for the pricing climate in the US. It isn’t an easy question to answer.

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel